Preclinical studies suggest GHRH antagonists as a low-toxicity cancer therapy, particularly in lung, prostate, breast, gastrointestinal cancers as well as acute myeloid leukemia and brain tumors [15, 16, 18, 19]. This evidence concerns the gene GHRH and cancer.